EDP Sciences logo
Subscriber Authentication Point
Rechercher
Menu
Accueil Tous les numéros Volume 41 / Numéro 8-9 (Août-Septembre 2025) Med Sci (Paris), 41 8-9 (2025) 693-700 References
Open Access
Issue
Med Sci (Paris)
Volume 41, Number 8-9, Août-Septembre 2025
Page(s) 693 - 700
Section Repères
DOI https://doi.org/10.1051/medsci/2025109
Published online 8 septembre 2025
  1. Hirschfield GM, Beuers U, Corpechot C, et al. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017 ; 67 : 145–72. [Google Scholar]
  2. Corpechot C, Gaouar F, Chrétien Y, et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol 2012 ; 56 : 218–24. [Google Scholar]
  3. Boonstra K, Kunst AE, Stadhouders PH, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int Off J Int Assoc Study Liver 2014 ; 34 : e31–8. [Google Scholar]
  4. Lleo A, Jepsen P, Morenghi E, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep 2016 ; 6 : 25906. [Google Scholar]
  5. Dahlan Y, Smith L, Simmonds D, et al. Pediatric-onset primary biliary cirrhosis. Gastroenterology 2003 ; 125 : 1476–9. [Google Scholar]
  6. Leung PSC, Rossaro L, Davis PA, et al. Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis. Hepatology 2007 ; 46 : 1436. [Google Scholar]
  7. Dahlqvist G, Gaouar F, Carrat F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatol Baltim Md 2017 ; 65 : 152–63. [Google Scholar]
  8. Corpechot C, Carrat F, Gaouar F, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol 2022 ; 77 : 1545–53. [Google Scholar]
  9. Lam L, Soret P-A, Lemoinne S, et al. Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis. clin gastroenterol hepatol 2024 ; 22 : 2432–2441.e2. [Google Scholar]
  10. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013 ; 144 : 560–69.e7. [Google Scholar]
  11. Trivedi PJ, Corpechot C, Pares A, et al. Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology 2016 ; 63 : 644. [Google Scholar]
  12. Vleggaar F, Buuren HR van, Zondervan P, et al. Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut 2001 ; 49 : 276–81. [Google Scholar]
  13. Gatselis NK, Goet JC, Zachou K, et al. Factors associated with progression and outcomes of early stage primary biliary cholangitis. Clin Gastroenterol Hepatol 2020 ; 18 : 684–692.e6. [Google Scholar]
  14. Björnsson E, Boberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002 ; 51 : 731–5. [Google Scholar]
  15. Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years. Gastroenterology 2002 ; 123 : 1044–51. [Google Scholar]
  16. Harms MH, Buuren HR van, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2019 ; 71 : 357–65. [Google Scholar]
  17. Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011 ; 55 : 1361–7. [Google Scholar]
  18. Murillo Perez CF, Harms MH, Lindor KD, et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol 2020 ; 115 : 1066–74. [Google Scholar]
  19. Corpechot C, Lemoinne S, Soret P-A, et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology 2024 ; 79 : 39. [Google Scholar]
  20. Dilger K, Hohenester S, Winkler-Budenhofer U, et al. Corrigendum to: “Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health” [J Hepatol 2012;57:133-140]. J Hepatol 2014 ; 60 : 684. [Google Scholar]
  21. Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006 ; 130 : 715–20. [Google Scholar]
  22. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005 ; 128 : 297–03. [Google Scholar]
  23. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008 ; 48 : 871. [Google Scholar]
  24. Poupon RE, Poupon R, Balkau B, et al. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994 ; 330 : 1342–7. [Google Scholar]
  25. Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015 ; 149 : 1804–12.e4. [Google Scholar]
  26. Nevens F, Andreone P, Mazzella G, et al. A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016 ; 375 : 631–43. [Google Scholar]
  27. Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015 ; 148 : 751–61.e8. [Google Scholar]
  28. Murillo Perez CF, Fisher H, Hiu S, et al. Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls. Gastroenterology 2022 ; 163 : 1630–42.e3. [Google Scholar]
  29. Kowdley KV, Hirschfield GM, Coombs C, et al. COBALT: A Confirmatory Trial of obeticholic acid in primary biliary cholangitis with placebo and external controls. Am J Gastroenterol 2025 ; 120 : 390–400. [Google Scholar]
  30. Corpechot C, Chazouillères O, Rousseau A, et al. A Placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018 ; 378 : 2171–81. [Google Scholar]
  31. Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 2014 ; 34 : 197–203. [Google Scholar]
  32. Tanaka A, Hirohara J, Nakano T, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2021 ; 75 : 565–71. [Google Scholar]
  33. Smets L, Verbeek J, Korf H, et al. Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate. Hepatol Baltim Md 2021 ; 73 : 2598–600. [Google Scholar]
  34. Soret P-A, Lam L, Carrat F, et al. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. Aliment Pharmacol Ther 2021 ; 53 : 1138–46. [Google Scholar]
  35. Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med 2024 ; 390 : 795–805. [Google Scholar]
  36. Hirschfield GM, Bowlus CL, Mayo MJ, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med 2024 ; 390 : 783–94. [Google Scholar]
  37. Giannini EG, Pasta A, Calabrese F, et al. Second-line treatment for patients with primary biliary cholangitis: a systematic review with network meta-analysis. Liver Int Off J Int Assoc Study Liver 2025 ; 45 : e16222. [Google Scholar]
  38. Hirschfield GM, Beuers U, Kupcinskas L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol 2021 ; 74 : 321–9. [Google Scholar]
  39. Harms MH, Janssen QP, Adam R, et al. Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Aliment Pharmacol Ther 2019 ; 49 : 285–95. [Google Scholar]
  40. Liermann Garcia RF, Garcia CE, McMaster P, et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001 ; 33 : 22. [Google Scholar]
  41. Montano-Loza AJ, Hansen BE, Corpechot C, et al. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival. Gastroenterology 2019 ; 156 : 96–107.e1. [Google Scholar]
  42. Montano-Loza AJ, Lytvyak E, Hirschfield G, et al. Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation. J Hepatol 2024 ; 81 : 679–89. [Google Scholar]
  43. Corpechot C, Chazouillères O, Belnou P, et al. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. J Hepatol 2020 ; 73 : 559–65. [Google Scholar]
  44. Hegade VS, Kendrick SFW, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 2017 ; 389 : 1114–23. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.